KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Interest Expenses (2019 - 2025)

Historic Interest Expenses for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $10.8 million.

  • GoodRx Holdings' Interest Expenses fell 1235.13% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year decrease of 2274.54%. This contributed to the annual value of $52.9 million for FY2024, which is 670.92% down from last year.
  • Per GoodRx Holdings' latest filing, its Interest Expenses stood at $10.8 million for Q3 2025, which was down 1235.13% from $10.7 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year Interest Expenses high stood at $14.8 million for Q4 2023, and its period low was $5.9 million during Q1 2022.
  • In the last 5 years, GoodRx Holdings' Interest Expenses had a median value of $10.8 million in 2025 and averaged $10.5 million.
  • As far as peak fluctuations go, GoodRx Holdings' Interest Expenses tumbled by 3163.93% in 2021, and later skyrocketed by 12376.9% in 2023.
  • Over the past 5 years, GoodRx Holdings' Interest Expenses (Quarter) stood at $5.9 million in 2021, then skyrocketed by 102.05% to $11.9 million in 2022, then grew by 24.26% to $14.8 million in 2023, then decreased by 23.37% to $11.4 million in 2024, then decreased by 4.66% to $10.8 million in 2025.
  • Its Interest Expenses stands at $10.8 million for Q3 2025, versus $10.7 million for Q2 2025 and $10.6 million for Q1 2025.